Assessment of Compliance With Antihypertensive Telmisartan Therapy

Bayer3,400 enrolled

Overview

The purpose of this study is to asses the efficacy and safety of Telmisartan depending on the use of an electronic therapy monitoring device (HelpingHand) in a real life setting and to asses patients compliance to the therapy with Telmisartan in relation to use of electronic therapy monitoring device.

Study Type

OBSERVATIONAL

Enrollment

3,400

Conditions

Hypertension

Interventions

Telmisartan (Kinzal/Pritor, BAY68-9291)DRUG

Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age over 18 * Untreated or ineffectively treated arterial hypertension Exclusion Criteria: * Cholestatic disorders and severe hepatic failure * Allergy to Telmisartan * Pregnancy and lactation period * Unwillingness to participate in the study * Inability to use the drug reminder device * Unwillingness to use the drug reminder device

Locations (2)

Unnamed facility

Many Locations, Poland

Unnamed facility

Many Locations, Slovakia

Outcomes

Primary Outcomes

Efficacy and safety of the treatment with telmisartan reported by the physician with regard to usage the HelpingHand device

Time frame: At all four planned control visits. (Approx. interval between visits 3 months)

Secondary Outcomes

Compliance with the treatment calculated on the basis of by HelpingHand and patients questionnaires

Time frame: At all four planned control visits. (Approx. interval between visits 3 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.